Projects
Towards the use of in vitro and in silico T-cell response prediction to guide the development of vaccines, using mRNA-based rabies vaccine as a proof-of-concept. University of Antwerp
The yellow fever vaccine at work: Mechanisms and platform for chronic hepatitis B and COVID-19 vaccines KU Leuven
The live-attenuated yellow fever virus (YFV) vaccine YF17D has been administered hundreds of millions of times, since its development in the 1930s. It is considered an outstanding vaccine, because of its efficacy, a consequence of its ability to activate multiple arms of the immune system upon inoculation. Anti-YFV neutralizing antibodies (nAbs) have long been considered to be sufficient and required for protection. We have challenged this ...
COVID19 – TriVoice PLUS – Astra-Zeneca derde dosis, Vaccination against Covid-19 in cancer: booster shot BNT161b2 vaccine after full vaccination with ChAdOx1-S vaccine (Tri-VOICE plus). University of Antwerp
European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates Vrije Universiteit Brussel
Next Steps in HBV Vaccine Research: Novel Small Animal Models for HBV Infection and Innovative Microneedle Patch-Based Vaccine Delivery Methods KU Leuven
More than 300 million people worldwide suffer from chronic hepatitis B. Current standard-of-care is based on the administration of suppressive antiviral therapies with the intent of decreasing viral titres and thus delaying any long-term effects of the disease. However, full clearance is rarely achieved and long-term exposure to the hepatitis B virus will imminently lead to detrimental effects on the liver, eventually resulting into the ...
Consortium Agreement concerning the EDCD-prject: "VACCINE PREVENTABLE DISEASES MODELLING IN THE EUROPEAN UNION AND EEA/EFTA COUNTRIES: FORECASTING TNHE EFFECT OF INTRODUCING A NEW VACCINE IN A NATIONAL/REGIONAL PROGRAM" Hasselt University
Evaluation of a novel vaccine delivery and expression platform-Plasmid Launched Live Attenuated Viral Vaccine (PLLAV) KU Leuven
Prof J.Neyts and his team is interested in
*encapsulation of model pDNA into lipid nanoparticles
*evaluate pDNA LNPs at a dose of 2.5µg/mice using intramuscular and subcutaneous injections
*evaluate the best performing formulations in hamster and pigs
Experimental plan:
use PNI's proprietary lipid compositions to screen processing conditions for encapsulation of model pNA, selection criteria: particle ...